ArticleClinical ophthalmology (Auckland, N.Z.)2026
Long Term Visual Outcomes Following Implantation of a New Hydrophobic IOL in a Real-World Clinical Setting.
Article in Clinical ophthalmology (Auckland, N.Z.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To assess long-term visual and patient-reported outcomes of the CNWTTx (Clareon Methods: A retrospective, non-comparative, real-world observational study performed on 70 eyes from 44 patients who underwent standard phacoemulsification and implantation of CNWTT0-T4 trifocal intraocular lens (IOLs) (Alcon Labs, Ft Worth, TX, USA). Postoperative testing was performed at 4-6 weeks following surgery and included monocular and binocular uncorrected distance (UDVA), intermediate (UIVA) and near (UNVA) visual acuity, distance-corrected intermediate (DCIVA) and near (DCNVA) visual acuity, manifest refraction, best corrected distance visual acuity (BCVA), stereoacuity, spectacle independence and monocular and binocular mesopic contrast sensitivity (CS). Visual symptoms were recorded using a subjective scale (nil, tolerable, bothersome) and satisfaction was recorded using a scale of 1 (least satisfied) to 10 (most satisfied). 6-12 months postoperative VA data on a subset of patients (N = 35 eyes) was available to monitor continued vision improvement. Results: Manifest refraction spherical equivalent (MRSE) was -0.12 ± 0.39 D (mean ± SD) with 88% achieving within ±0.5 D of the refractive target. Postoperative monocular UDVA and BCVA (mean ± SD) were 0.05 ± 0.10 LogMAR and -0.01 ± 0.07 LogMAR, with 61% and 90% achieving 0.0 LogMAR or better, respectively. Sixty percent of eyes monocularly achieved N5 (approximately 0.18 LogMAR) or better unaided at near, 77% achieved N6 (approximately 0.2 LogMAR) or better at near, and 68.0% achieved N8 (approximately 0.1 to 0.2 LogMAR) or better at intermediate. Mean postoperative binocular CS was 1.67 ± 0.26 and mean stereoacuity was 124.63 ± 124.35 sec arc. Mean subjective satisfaction score was 8.74 ± 1.12. Bothersome glare and halos were reported by 10% and 4.3% of patients, respectively. Full spectacle independence was reported by 92.3% of bilaterally implanted patients. Conclusion: The CNWTTx IOL provides good vision at all ranges with the majority of patients not requiring spectacles for daily tasks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.